Contact

Please select a country

us@pharmalex.com

Contact United States

TwitterLinkedin
contact@pharmalex.com
Search
PharmaLexPharmaLex
PharmaLex
Confidence Beyond Compliance
  • About Us
    • About Us
    • Management Team
    • Industry Expertise
      • Biopharma
      • Customer On-site Support
      • Medical Device Services
      • Portfolio Maintenance Outsourcing
    • What Our Clients Say About Us
    • Our Approach
    • Resource Library
  • Our Services
    • Choose a Service
    • InnoPHLEX
    • SourcePHLEX
    • Development Consulting
    • Regulatory Affairs
    • Quality Management & Compliance
    • Pharmacovigilance, Epidemiology & Risk Management
    • Medical Device Services
    • Brexit
  • News & Events
    • News
    • Webinars
    • Events
  • Countries
  • Contact us
  • Careers
    • Current Opportunities
    • Why work at PharmaLex
    • Working at PharmaLex
Menu back  
Home > News & Events > Global > Interview with David Jefferys on “Brexit – possible implications”

Interview with David Jefferys on “Brexit – possible implications”

During our office opening event in Munich on the 17th of May 2017, we took the opportunity to discuss the possible implications of Brexit in the life science industry with our guest speaker, David Jefferys.

David Jefferys is currently the Senior Vice President for Global Regulatory, Healthcare Policy and Corporate Affairs, Eisai Europe as well as Chairman of the Eisai Global Regulatory Council. David trained as a physician  and after a career in clinical and academic medicine, spent 21 years as a senior Medicines and Medical Device Regulator in the UK and in Europe. He was Director of the Licensing Division and an executive director of the Medicines Control Agency. During this time he served as the principal assessor to the Committee on the Safety of Medicines. In his career, David has worked closely with the EU Commission and on secondment with the EMA on benefit/risk evaluation. For 16 years he was the UK delegate to the CPMP/ CHMP. He has worked in industry for more than 12 years and chairs both the ABPI and the Efpia Regulatory Committees. Within IFPMA, he co-chairs the Regulatory Policy and Standards Committee and attends the Council meetings. He is the IFPMA Standing Observer to ICH. He is a past President of RAPS and TOPRA, as well as a member of the Board of Pharmaceutical Physicians.
He is therefore, in a unique position to comment on the possible issues generated by Brexit and to discuss both the opportunities and the threats posed to the Life Science sector.

David agreed to join Carolyn Belcher – Executive Vice President of Development Consulting at PharmaLex – for a short interview. This is the first part of the series which we hope you find informative and insightful.

Please watch the second part of the interview with David Jefferys below. After discussing the main considerations for the pharmaceutical industry in the advancement of Brexit and the different possible scenarios the UK is facing, David focuses on  cooperation between the UK and the remaining EEA countries in the second half of the interview.

Related posts
Pharmaceutical Serialisation – Are you Ready?
23rd November 2018
Can an Appropriate Risk-Benefit Assessment Help Drug Availability?
15th November 2018
HPRA Guide Update to “Notification of Marketing Status of Human Medicines”
8th November 2018
HPRA Guide Update to “Batch-Specific Requests for Human Medicines”
1st November 2018
HPRA Guide Update to “Labels and Leaflets of Human Medicines”
23rd October 2018
How is Brexit impacting Pharma ?
10th October 2018
Search
Recent News
  • Top 10 Tips for an effective Internal Audit System
    20th February 2019
  • Use and Learn Period for Serialisation
    14th February 2019
  • Cleaning Validation
    13th February 2019
  • Brexit: Update for the Pharma Industry
    7th February 2019
  • How can you add value to your Self-Inspection Programme?
    30th January 2019
  • Webinar // Early Phase Modelling – Estimating the Costs and Effectiveness of a Pharmaceutical before Clinical Trial
    25th January 2019
Categories
  • All News
  • Webinars
  • Events
Archive
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
  • Will you be at DIA RSIDM 2019 in North Bethesda? If you are, make sure you stop by our booth and say hello.… https://t.co/tMVDOLWmw524 days ago
  • Take part in our survey on pharmaceutical serialization. It only takes a few minutes and helps us identify some of… https://t.co/bw1DQP5N3224 days ago
NEWSLETTER SIGN UP










View our privacy policy

WHAT OUR CLIENTS SAY
  • PharmaLex is dedicated to delivering a comprehensive portfolio while their modular approach allows tailor-made solutions. They acknowledge our feedback, modify their approach and adapt accordingly.

    Top 10 Pharma Company
    President
PharmaLex
©2018 PharmaLex GmbH. All rights reserved.

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. These emails are being sent from @pharmalexcompanies.com and are not from us. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.

Privacy Policy

This can be specific information about signing up to the newsletter.

Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.

Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.